- Announces co-exclusive licensing agreement with Sanofi (NASDAQ:) to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax (NASDAQ:)’s Matrix-M™ adjuvant
- This agreement represents a potential multi-billion dollar revenue opportunity for Novavax including:
$500 million upfront payment- Approximately
$70 million equity investment in Novavax - Up to
$700 million in COVID-19 and combination product near-term milestones, plus ongoing tiered royalties on product sales - Up to
$200 million in milestones plus royalties for each new vaccine developed utilizing Novavax’s Matrix-M™ adjuvant
- Announces addition of standalone influenza vaccine to Phase 3 COVID-19-Influenza Combination vaccine trial, which is on-track to initiate second half of 2024, with potential 2026 launch for both candidates
- Reduced current liabilities by an additional
$831 million during Q1 2024 - Achieved total revenue in Q1 2024 of
$94 million - Novavax removes going concern notice
- Company to host conference call today at
8:30 a.m. ET
Earlier today, Novavax and Sanofi (NASDAQ: SNY) announced that they have entered into a co-exclusive licensing agreement. The terms of the agreement include: a co-exclusive license to co-commercialize Novavax’s current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements [APAs] and in
“Today we announce the beginning of an exciting new chapter for Novavax with the launch of a strategically important partnership with one of the world’s leading vaccine companies. We believe the combined strength of Novavax and Sanofi will enable us to…
Click Here to Read the Full Original Article at All News…